We serve Chemical Name:2,3,3′,4,6-Pentachlorobiphenyl CAS:74472-35-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,3,3′,4,6-Pentachlorobiphenyl
CAS.NO:74472-35-8
Synonyms:1,2,3,5-tetrachloro-4-(3-chlorophenyl)benzene
Molecular Formula:C12H5Cl5
Molecular Weight:326.43300
HS Code:
Physical and Chemical Properties:
Melting point:95.86°C (estimate)
Boiling point:373ºC at 760mmHg
Density:1.522g/cm3
Index of Refraction:1.619
PSA:
Exact Mass:323.88300
LogP:6.62060
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1,2,3,5-tetrachloro-4-(3-chlorophenyl)benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,3,5-tetrachloro-4-(3-chlorophenyl)benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2,3,5-tetrachloro-4-(3-chlorophenyl)benzene Use and application,1,2,3,5-tetrachloro-4-(3-chlorophenyl)benzene technical grade,usp/ep/jp grade.
Related News: Government officials say that the number of visitors from the mainland and other countries has decreased significantly after they closed several border points and rail stations and cut flight arrivals by half. 2,3,3′,4,6-Pentachlorobiphenyl manufacturer With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout. 2,3,3′,4,6-Pentachlorobiphenyl supplier There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. 2,3,3′,4,6-Pentachlorobiphenyl vendor Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. 2,3,3′,4,6-Pentachlorobiphenyl factory There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association.
